The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors

British Journal of Pharmacology

Volumn 172, Issue 24, 2015, Pages 5979-6023

  Alexander, Stephen Ph ^a   Fabbro, Doriano ^b   Kelly, Eamonn ^c   Marrion, Neil ^c   Peters, John A ^d   Benson, Helen E ^e   Faccenda, Elena ^e   Pawson, Adam J ^e   Sharman, Joanna L ^e   Southan, Christopher ^e   Davies, Jamie A ^e  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Piqur Therapeutics AG   (Switzerland)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; CATALYTIC RECEPTOR; CELL SURFACE PROTEIN; CYTOKINE RECEPTOR; EPHRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; INSULIN RECEPTOR; INTEGRIN; INTERFERON RECEPTOR; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3 RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NEUROTROPHIN RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROLACTIN RECEPTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE RECEPTOR 1; PROTEIN SERINE THREONINE KINASE RECEPTOR 2; PROTEIN SERINE THREONINE KINASE RECEPTOR 3; PROTEIN TYROSINE KINASE; SCATTER FACTOR; TETRAGASTRIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; CELL SURFACE RECEPTOR; LIGAND;

ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; CATALYSIS; CELL COMMUNICATION; DIMERIZATION; ENZYME ACTIVITY; HUMAN; LIGAND BINDING; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DRUG DATABASE; DRUG EFFECTS;

ANIMALS; DATABASES, PHARMACEUTICAL; HUMANS; LIGANDS; RECEPTORS, CELL SURFACE;

EID: 84949818215     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13353     Document Type: Article

References (209)

1. (2004) [15293871]
2. Akeno-Stuart N, et al., (2007) [17638907]
3. Akeson AL, et al., (1996) [8940020]
4. Albaugh P, et al., (2012) [24900443]
5. Albaugh P, et al., (2012) [24900443]
6. Alexopoulou L, et al., (2001)
7. Apsel B, et al., (2008) [18849971]
8. Arena S, et al., (2007) [17595299]
9. AstraZeneca,. AZD1332. Accessed on 11/09/2014. AstraZeneca.com
10. Batley BL, et al., (1998) [9488112]
11. Beebe JS, et al., (2003) [14612527]
12. Berger C, et al., (2013) Compositions and methods for increasing muscle growth. Patent number: US8388968. Assignee: Novartis Ag. Priority date: 27/04/2009. Publication date: 05/03/2013.
13. Bhide RS, et al., (2006) [16570908]
14. Blume-Jensen P, et al., (2001) [11357143]
15. Bold G, et al., (2000) [10882357]
16. Bouyain S, et al., (2010) [20133774]
17. Brasca MG, et al., (2009) [19603809]
18. Bryant CE, et al., (2015) [25829385]
19. Buchanan SG, et al., (2009) [19934279]
20. Busby RW, et al., (2010) [20863829]
21. Cardarelli JM, et al., (2010) Interferon alpha receptor I antibodies and their use. Patent number: US7662381. Assignee: Medarex, Inc. Priority date: 21/06/2004. Publication date: 16/02/2010.
22. Carlomagno F, et al., (2002) [12499271]
23. Cazorla M, et al., (2011) [21505263]
24. Cho TP, et al., (2010) [21028894]
25. Choi SJ, et al., (2010) [20153646]
26. Christensen JG, et al., (2003) [14612533]
27. Clemens GR, et al., (2009) [19107952]
28. Cockerill S, et al., (2001) [11378364]
29. Cohen ES, et al., (2012) Antibody molecule for human GM-CSF receptor alpha. Patent number: US8263075. Assignee: Medimmune Limited. Priority date: 27/03/2006. Publication date: 11/09/2012.
30. Coll RC, et al., (2015) [25686105]
31. Coller BS, et al., (1999) Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3. Patent number: US5976532. Assignee: Centocor, Inc. Priority date: 18/05/1988. Publication date: 02/11/1999.
32. Conway JG, et al., (2005) [16249345]
33. Coumar MS, et al., (2010) [20550212]
34. Cui JJ, et al., (2012) [22924734]
35. Cui JJ, et al., (2011) [21812414]
36. DaCosta Byfield S, et al., (2004) [14978253]
37. Davis BK, et al., (2011) [21219188]
38. Davis MI, et al., (2011) [22037378]
39. Day E, et al., (2008) [18938156]
40. Dechant G, et al., (1997) [9204912]
41. Delporte C, et al., (1991) [1680722]
42. Deschênes J, et al., (2005) [15652659]
43. Ding X, et al., (2012) [22516751]
44. Dripps DJ, et al., (1991) [1834644]
45. Engersm DW, et al., (2013) [23639540]
46. Eriksson A, et al., (2012) [22864397]
47. Fabbro D, et al., (2012) [21960212]
48. Fan Q, et al., (2006) [16982323]
49. Fraley ME, et al., (2002) [12443771]
50. Gable KL, et al., (2006) [16648580]
51. Gao M, et al., (2013) [23521020]
52. Gaozza E, et al., (1997) [9444961]
53. García-Echeverría C, et al., (2004) [15050915]
54. Gaul MD, et al., (2003) [12639547]
55. Gazit A, et al., (1991) [1676428]
56. Gazit A, et al., (1989) [2552117]
57. Gendreau SB, et al., (2007) [17575237]
58. Gerber DE, et al., (2010) [21156280]
59. Gingrich DE, et al., (2012) [22564207]
60. Goldstein NI, et al., (2006) Epidermal growth factor; nucleic acids, protein which binds to epidermal growth factor receptors; genetic engineering. Patent number: US7060808. Assignee: Imclone Systems Incorporated. Priority date: 07/06/1995. Publication date: 13/06/2006.
61. Goodman SL, et al., (2002) [11855984]
62. Grassot J, et al., (2003) [12520021]
63. Graus-Porta D, et al., (1997) [9130710]
64. Grumolato L, et al., (2010) [21078818]
65. Gundla R, et al., (2008) [18500794]
66. Hamra FK, et al., (1997) [9122260]
67. Harris LA, et al., (2007) [17694454]
68. Harris PA, et al., (2008) [18620382]
69. Hayashi F, et al., (2001) [11323673]
70. Heil F, et al., (2003) [14579267]
71. Heinrich MC, et al., (2012) [22745105]
72. Hemmi H, et al., (2002) [11812998]
73. Hemmi H, et al., (2000) [11130078]
74. Hilberg F, et al., (2008) [18559524]
75. Hobbs A, et al., (2004) [15337698]
76. Huang Q, et al., (2014) [24432909]
77. Hudkins RL, et al., (2012) [22148921]
78. Hunt DM, et al., (2010) [19941038]
79. Incerti M, et al., (2013) [23489211]
80. Ingalls RR, et al., (1998) [9820516]
81. Jardieu PM, et al., (2004) Method of treatment using humanized anti-CD11a antibodies. Patent number: US6703018. Assignee: Genentech, Inc. Priority date: 27/11/1996. Publication date: 19/03/2004.
82. Jin CH, et al., (2014) [24786585]
83. Kambayashi Y, et al., (1989) [2542088]
84. Kao Y-H, et al., (2006) Her2 antibody composition. Patent number: WO2006033700. Assignee: Genentech Inc. Priority date: 22/07/2004. Publication date: 30/04/2010.
85. Kawasaki K, et al., (2000) [10644670]
86. Kelly LM, et al., (2002) [12124172]
87. Khanwelkar RR, et al., (2010) [20570526]
88. Kim MH, et al., (2012) [22765894]
89. Kim N, et al., (2008) [18848351]
90. Kim YS, et al., (2011) [21094132]
91. Kitagawa D, et al., (2013) [23279183]
92. Klein RD, et al., (1997) [9192898]
93. Koike M, et al., (2013) Methods of reducing eosinophil levels. Patent number: US8501176. Assignee: Medimmune, Llc, Biowa, Inc. Priority date: 14/05/2007. Publication date: 06/08/2013.
94. Kubo K, et al., (2005) [15743179]
95. Kurachi H, et al., (1992) [1530648]
96. Kwon SK, et al., (2010) [20139422]
97. Lafleur K, et al., (2009) [19788238]
98. Lamphier M, et al., (2014) [24342772]
99. Lee HK, et al., (2014) [24532805]
100. Lee K, et al., (2010) [20869793]
101. Lee Y, et al., (2004) [15634795]
102. Lemmon MA, et al., (2010) [20602996]
103. Li D, et al., (2008) [18408761]
104. Li HY, et al., (2006) [16539403]
105. Li MO, et al., (2008) [18692464]
106. Li S, et al., (2013) [23644189]
107. Liang G, et al., (2012) [22884522]
108. Lin Kc, et al., (1999) [10072689]
109. Liu G, et al., (2012) [24900421]
110. Liu G, et al., (2000) [11052808]
111. Liu M, et al., (2009) Used in treating neoplastic diseases and hyperproliferative disorders. Patent number: US7598350. Assignee: Imclone Llc. Priority date: 19/03/ 2004. Publication date: 06/10/2009.
112. Liu X, et al., (2011) [21918175]
113. Lu D, et al., (2003) [12917408]
114. Maack T, et al., (1987) [2823385]
115. MacDonald RG, et al., (1988) [2964083]
116. Manthey CL, et al., (2009) [19887542]
117. Marathe P, et al., (2010) [20166197]
118. Marcinkiewicz C, et al., (2003) [12727812]
119. Marsilje TH, et al., (2008) [18783949]
120. Marsilje TH, et al., (2013) [23742252]
121. Martin JH, et al., (2009) Cytokine specific immunoglobulin for use in diagnosis, prevention and treatment,of cell proliferative, inflammatory, allergic, respiratory, autoimmune and arthritic disorders. Patent number: US7608693. Assignee: Regeneron Pharmaceuticals, Inc. Priority date: 02/10/2006. Publication date: 27/10/2009.
122. Martinon F, et al., (2006) [16407889]
123. Massa SM, et al., (2010) [20407211]
124. Matsuno H, et al., (1994) [7955174]
125. Melisi D, et al., (2008) [18413796]
126. Mendel DB, et al., (2003) [12538485]
127. Meng K, et al., (2000) [10706604]
128. Miller MW, et al., (2009) [19141632]
129. Moffatt P, et al., (2007) [17951249]
130. Mollard A, et al., (2011) [22247788]
131. Mologni L, et al., (2006) [17032739]
132. Morishita Y, et al., (1991) [1674870]
133. Morokata T, et al., (2002) [12469943]
134. Moustakas A, et al., (2009) [19855013]
135. Munshi N, et al., (2010) [20484018]
136. Murthy KS, et al., (1999) [10364194]
137. Musumeci F, et al., (2012) [23098265]
138. Nagata K, et al., (1996) [8939948]
139. Nakagawa T, et al., (2010) [19832844]
140. Nam HJ, et al., (2011) [21306821]
141. Ohashi K, et al., (2000) [10623794]
142. Ohmichi M, et al., (1993) [7683492]
143. Ohno H, et al., (2006) [17121910]
144. Olson LJ, et al., (1996) [8700153]
145. Ornitz DM, et al., (1996) [8663044]
146. Pan BS, et al., (2010) [20145145]
147. Patyna S, et al., (2006) [16891463]
148. Pearson MA, et al., (2004) [15606337]
149. Pollard JR, et al., (2009) [19320489]
150. Poltorak A, et al., (1998) [9851930]
151. Ponath PD, et al., (2006) Humanized immunoglobulin reactive with α4β7 integrin. Patent number: US7147851 B1. Assignee: Millennium Pharmaceuticals, Inc. Priority date: 15/08/1996. Publication date: 12/12/2006.
152. Puppo F, et al., (2011) [21132015]
153. Párrizas M, et al., (1997) [9075698]
154. Queen CL, et al., (1997) Genetic engineering; complementarity zones. Patent number: US5693761. Assignee: Protein Design Labs, Inc. Priority date: 28/12/1988. Publication date: 02/12/1997.
155. Rabindran SK, et al., (2004) [15173008]
156. Raghunath M, et al., (2000) [10837911]
157. Renhowe PA, et al., (2009) [19113866]
158. Roberts WG, et al., (2005) [15705896]
159. Rusnak DW, et al., (2001) [12467226]
160. Sabbah A, et al., (2009) [19701189]
161. Sabbatini P, et al., (2009) [19825801]
162. Sattler M, et al., (2003) [14500382]
163. Schroder K, et al., (2010) [20303873]
164. Schroeder GM, et al., (2009) [19260711]
165. Schwandner R, et al., (1999) [10364168]
166. Shen Y, et al., (2009) [19833921]
167. Shi Y, et al., (2003) [12809600]
168. Shiotsu Y, et al., (2009) [19541823]
169. Skaper SD, et al., (2000) [10987832]
170. Smaill JB, et al., (2000) [10753475]
171. Stevens S, et al., (2009) High affinity antibodies to human IL-6 receptor. Patent number: US7582298. Assignee: Regeneron Pharmaceuticals, Inc. Priority date: 02/06/2006. Publication date: 01/09/2009.
172. Stitt TN, et al., (1995) [7867073]
173. Suga S, et al., (1992) [1309330]
174. Takeuchi O, et al., (2010) [20303872]
175. Takeuchi O, et al., (2001) [11431423]
176. Takeuchi O, et al., (2002) [12077222]
177. Tilley JW, et al., (1997) Identification of a small molecule inhibitor of the IL-2/IL-2R alpha receptor interaction which binds to IL-2. Journal of the American Chemical Society 119: 7589-7590.
178. Ting JP, et al., (2008) [18341998]
179. Tocker J, et al., (2010) Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto. Patent number: US7767206. Assignee: Amgen Inc. Priority date: 02/10/2006. Publication date: 03/08/2010.
180. Trainer PJ, et al., (2000) [10770982]
181. Traxler P, et al., (1999) [10090785]
182. Treanor JJ, et al., (1996) [8657309]
183. Trudel S, et al., (2005) [15598814]
184. Ullrich A, et al., (1990) [2158859]
185. Veale CA, et al., (2000) [10987424]
186. Vogt J, et al., (2011) [21740966]
187. Walter AO, et al., (2013) [24065731]
188. Walzel H, et al., (1999) [10369126]
189. Wang T, et al., (2012) [24900538]
190. Wang X, et al., (2003) [14617781]
191. Ward AC, et al., (2000) [10607680]
192. Weisberg E, et al., (2002) [12124173]
193. Weisberg E, et al., (2008) [18820131]
194. Wesche J, et al., (2011) [21711248]
195. Whittles CE, et al., (2002) [12483548]
196. Wilhelm SM, et al., (2004) [15466206]
197. Wissner A, et al., (2007) [17416531]
198. Wittman M, et al., (2005) [16134929]
199. Wittman MD, et al., (2009) [19778024]
200. Wood ER, et al., (2004) [15013000]
201. Wu H, et al., (2010) Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity. Patent number: US7659374. Assignee: Medimmune, Llc. Priority date: 16/08/2004. Publication date: 09/02/2010.
202. Wyss DF, et al., (1991) [1826288]
203. Yakes FM, et al., (2011) [21926191]
204. Yan M, et al., (2000) [11039935]
205. Yoshimura A, et al., (1999) [10384090]
206. Zarrinkar PP, et al., (2009) [19654408]
207. Zhang YM, et al., (2004) [14684309]
208. Zhao G, et al., (2011) [21900693]
209. Zhou G, et al., (2001) [11602624]